- PR Newswire•9 hours ago
MONMOUTH JUNCTION, N.J., Sept. 29, 2016 /PRNewswire/ -- CytoSorbents Corporation (CTSO) a critical care immunotherapy company working to save lives through blood purification, announced the launch of its newly redesigned corporate website, CytoSorbents.com. The new site highlights CytoSorbents' rapid international growth and leadership in treating deadly inflammation in critical illnesses and cardiac surgery with its flagship product, CytoSorb®, and reflects the broad new growth opportunities of its expanding and innovative product pipeline. Visitors to the new site will find a wealth of new and streamlined information on CytoSorbents' pioneering blood purification technology and how it is being adapted to address many of most pressing unmet medical needs. Physicians, patients, customers, journalists, and potential partners will receive a complete overview of CytoSorb® and its role in helping to save lives, before being redirected to the official CytoSorb product website where an even greater level of detail awaits. Investors will find key technical and financial information about the company, updates on its world-class strategic partners, summaries of clinical data, archived presentations and multimedia, the ability to join the company's email news list, a quick link to the company's Facebook, Twitter, and LinkedIn pages, and more.
- PR Newswire•6 days ago
Mr. Mohammadreza Hosseini, Chief Executive Officer of Armaghan Salamat Kish stated, "This is a historic moment. In the past, we have seen many hospitalized patients fall victim to sepsis, the systemic inflammatory response syndrome (SIRS), and other related critical conditions.
- PR Newswire•14 days ago
MONMOUTH JUNCTION, N.J., Sept. 15, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy using its CytoSorb® blood purification technology to help patients ...
Cytosorbents Corporation (CTSO)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||6.14 x 100|
|Ask||6.23 x 400|
|Day's Range||6.10 - 6.22|
|52wk Range||3.11 - 8.10|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-16.11|
|Avg Vol (3m)||72,503|
|Dividend & Yield||N/A (N/A)|